Previsioni del mercato europeo dei prodotti terapeutici per le malattie infettive fino al 2030 - Analisi regionale - per classe di farmaci (antivirali, antibatterici, antifungini e altri), indicazione (HIV, epatite, tubercolosi, influenza, HPV e altri), via di somministrazione (orale, parenterale, topica e altri) e canale di distribuzione (farmacie ospedaliere, farmacie al dettaglio e altri)
La crescente attenzione ai finanziamenti e alla ricerca e sviluppo nella terapia delle malattie infettive guida il mercato europeo della terapia delle malattie infettive
La ricerca e lo sviluppo (R&S) sono una parte fondamentale del business dei prodotti biofarmaceutici e delle aziende farmaceutiche. La ricerca e sviluppo consente loro di lanciare nuovi prodotti per diverse applicazioni terapeutiche con un significativo potenziale medico e commerciale. Inoltre, i principali attori del mercato stanno investendo in ricerca e sviluppo per sviluppare tecnologie avanzate e ottenere una maggiore quota di ricavi.
Per creare soluzioni ai più importanti problemi sanitari che l\'Europa e il resto del mondo stanno attualmente affrontando, l\'Unione Europea sta investendo in ricerca, tecnologia e innovazione. La Commissione europea ha aperto la strada alla promozione della ricerca, in particolare quella relativa all’immunità e alla gestione delle malattie infettive. Tra il 2007 e il 2019 sono stati stanziati oltre 4,3 miliardi di dollari (4 miliardi) per lo studio delle malattie infettive. Inoltre, Orizzonte Europa, l’imminente iniziativa di finanziamento dell’UE per la ricerca e l’innovazione (R&I) (2021-2027), continuerà a sostenere la ricerca e l’innovazione per le malattie infettive, in particolare quelle associate alla povertà, quelle trascurate e quelle che sono (ri- )emergente.
Horizon Europe è un programma dedicato al sostegno della ricerca e dell\'innovazione. Per superare le barriere tra le regioni e stabilire collaborazioni tangibili, il programma pone un forte accento sulla garanzia della cooperazione tra università, comunità scientifiche, industria, in particolare piccole e medie imprese, e individui. Il programma di lavoro sanitario delinea le opzioni di finanziamento nell’ambito di Orizzonte Europa per la ricerca relativa alle malattie infettive e alla preparazione e risposta alle pandemie. Pertanto, la crescente attenzione alla ricerca e sviluppo e ai finanziamenti nelle terapie per le malattie infettive guidano la crescita del mercato delle terapie per le malattie infettive.
Panoramica del mercato europeo delle terapie per le malattie infettive
Il mercato europeo delle terapie per le malattie infettive è segmentato in Germania, Regno Unito, Francia, Italia, Spagna e resto d\'Europa. L’Europa occupa una posizione significativa nel mercato globale delle terapie per le malattie infettive e si stima registrerà un CAGR notevole nel periodo 2022-2030. La regione ha una maggiore incidenza di malattie virali croniche e una forte domanda per lo sviluppo di nuovi farmaci antivirali. Con 15,79 miliardi di dollari finanziati dal 2007 al 2019 attraverso il 7° programma quadro e Orizzonte 2020 e 1,1 miliardi di dollari stanziati per la ricerca sul Covid-19, l’Europa svolge un ruolo cruciale nel finanziamento e nel coordinamento della ricerca sulle malattie infettive. Secondo il Robert Koch Institute, in Germania, ogni anno circa 400.000-600.000 pazienti soffrono di un\'infezione contratta in ospedale, di cui 10.000-15.000 muoiono. I problemi tipici per gli operatori sanitari sono le infezioni del sito chirurgico, le infezioni del tratto urinario e la polmonite. La domanda di agenti antinfettivi in Germania sta crescendo in modo significativo, a causa dell’aumento della popolazione geriatrica, della crescente prevalenza di malattie virali croniche e della crescente domanda di produrre nuove molecole per le aree terapeutiche virali per soddisfare condizioni non soddisfatte. La Germania è una delle nazioni leader per la produzione di agenti antivirali e per il potenziale di crescita in Europa grazie all’elevata qualità dei suoi prodotti finiti. Ad esempio, Atriva Therapeutics GmbH, un’azienda biofarmaceutica, ha sviluppato ATR-002 per trattare pazienti affetti da COVID-19 in uno studio di Fase II per bloccare la propagazione virale di SARS-CoV-2. Pertanto, a causa dei fattori sopra menzionati, si prevede che il mercato crescerà in modo significativo nel paese.
Entrate e previsioni del mercato europeo delle terapie per le malattie infettive fino al 2030 (milioni di dollari)
Segmentazione del mercato europeo delle terapie per le malattie infettive
Il mercato europeo delle terapie per le malattie infettive è classificato in classi di farmaci , indicazione, via di somministrazione, canale di distribuzione e paese.
In base alla classe di farmaci, il mercato europeo delle terapie per le malattie infettive è segmentato in antivirali, antibatterici, antifungini e altri. Il segmento antivirale ha detenuto la quota di mercato maggiore nel 2022.
In termini di indicazione, il mercato europeo delle terapie per le malattie infettive è segmentato in HIV, epatite, tubercolosi, influenza, HPV e altri. L\'HIV ha detenuto la quota di mercato maggiore nel 2022.
In base alla via di somministrazione, il mercato europeo delle terapie per le malattie infettive è segmentato in orale, parenterale, topico e altri. Il segmento orale ha detenuto la quota di mercato maggiore nel 2022.
In termini di canale di distribuzione, il mercato europeo delle terapie per le malattie infettive è segmentato in farmacie ospedaliere, farmacie al dettaglio e altri. Le farmacie ospedaliere detenevano la quota di mercato maggiore nel 2022.
Per paese, il mercato europeo delle terapie per le malattie infettive è segmentato in Germania, Regno Unito, Francia, Italia, Spagna e resto d\'Europa. La Germania ha dominato la quota di mercato europea delle terapie per le malattie infettive nel 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, BioCryst Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc, Merck & Co Inc, Pfizer Inc e Shionogi & Co Ltd sono alcune delle aziende leader che operano nel mercato europeo delle terapie per le malattie infettive.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.1 Europe Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. Infectious Disease Therapeutics Market - Europe Analysis
5.1 Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Europe Infectious Disease Therapeutics Market Analysis - by Indication
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Infectious Disease Therapeutics Market - Country Analysis
10.1 Europe Infectious Disease Therapeutics Market
10.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 Europe Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Germany: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 Germany: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 Germany: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 Germany: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 United Kingdom: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 France: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 France: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 France: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 France: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Italy: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Italy: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Italy: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
10.1.1.9.4 Italy: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.10 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.10.1 Overview
10.1.1.11 Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.11.1 Spain: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.11.2 Spain: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.11.3 Spain: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.11.4 Spain: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.12 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.12.1 Overview
10.1.1.13 Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.13.1 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.13.2 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.13.3 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.13.4 Rest of Europe: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Infectious Disease Therapeutics Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Shionogi & Co Ltd
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Bayer AG
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 BioCryst Pharmaceuticals Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 GSK Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 AbbVie Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Merck & Co Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Astellas Pharma Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
List of Tables
Table 1. Europe Infectious Disease Therapeutics Market Segmentation
Table 2. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 7. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 20. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 21. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
Table 22. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 23. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 24. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 25. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 26. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 27. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 28. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 29. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 30. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market
List of Figures
Figure 1. Europe Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Europe Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Europe Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Europe Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Europe Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Germany: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. United Kingdom: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. France: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Italy: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Spain: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Europe: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market
1. AbbVie Inc
2. Astellas Pharma Inc
3. Bayer AG
4. BioCryst Pharmaceuticals Inc
5. F. Hoffmann-La Roche Ltd
6. Gilead Sciences Inc
7. GSK Plc
8. Merck & Co Inc
9. Pfizer Inc
10. Shionogi & Co Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe infectious disease therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe infectious disease therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe infectious disease therapeutics market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.